###begin article-title 0
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
###end article-title 0
###begin p 1
###xml 88 102 88 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Histopathology</italic>
###xml 102 105 102 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">53,</bold>
Marquard L, Gjerdrum L M, Christensen Ib J, Jensen P B, Sehested M & Ralfkiaer E (2008) Histopathology53, 267-277
###end p 1
###begin p 2
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 2
###begin p 3
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
###end p 3
###begin title 4
Aims:
###end title 4
###begin p 5
Aberrant histone acetylation has been associated with malignancy and histone deacetylase (HDAC) inhibitors are currently being investigated in numerous clinical trials. So far, the malignancy most sensitive to HDAC inhibitors has been cutaneous T-cell lymphoma (CTCL). The reason for this sensitivity is unclear and studies on HDAC expression and histone acetylation in CTCL are lacking. The aim of this study was to address this issue.
###end p 5
###begin title 6
Methods and results:
###end title 6
###begin p 7
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 329 330 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 576 577 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The immunohistochemical expression of HDAC1, HDAC2, HDAC6, and acetylated H4 was examined in 73 CTCLs and the results related to histological subtypes and overall survival. HDAC1 was most abundantly expressed (P < 0.0001), followed by HDAC2; HDAC6 and H4 acetylation were equally expressed. HDAC2 (P = 0.001) and H4 acetylation (P = 0.03) were significantly more common in aggressive than indolent CTCL subtypes. In contrast, no differences were observed for HDAC1 and HDAC6. In a Cox analysis, elevated HDAC6 was the only parameter showing significant influence on survival (P = 0.04).
###end p 7
###begin title 8
Conclusions:
###end title 8
###begin p 9
High expression of HDAC2 and acetylated H4 is more common in aggressive than indolent CTCL. HDAC6 expression is associated with a favorable outcome independent of the subtype.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 497 498 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin's lymphomas defined by clonal proliferation of skin-homing malignant T lymphocytes. CTCL vary from indolent subtypes such as plaque lesions of mycosis fungoides (MF) to more aggressive phenotypes, such as Sezary syndrome (SS) and CD30- peripheral T-cell lymphomas. Survival rates are significantly different between patients with indolent and aggressive phenotypes. Hence, the 5-year survival rate for indolent CTCL is 90%1-3 compared with a <33% 5-year survival rate for aggressive CTCL.1-3
###end p 11
###begin p 12
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Whereas early MF is well controlled by skin-directed therapies or phototherapy,4-9 patients with more aggressive subtypes require systemic therapy. Interferons, retinoids, single-agent or combined chemotherapy have been used,10,11 but relapses are frequent12,13 and most drugs have not improved long-term survival.10,11,14,15 New therapies are thus needed for treating CTCL.
###end p 12
###begin p 13
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 824 826 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1168 1170 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 1479 1481 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 1482 1484 1482 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
Histone deacetylase (HDAC) inhibitors are a promising group of drugs in the treatment of both solid and haematological malignancies. By targeting of HDAC enzymes,16 they cause acetylation of core histones and other proteins.17 HDAC inhibitors can either be pan-inhibitors that target all 11 isoforms of HDAC enzymes, or selective inhibitors that target specific isoforms or subclasses of HDAC.18 HDACs are, together with histone acetyltransferases (HATs), involved in the regulation of transcriptional activity through acetylation and deacetylation of specific lysine residues on core histones. In general, histone acetylation through HAT activity leads to increased transcriptional activity, whereas deacetylation through HDAC activity leads to transcriptional repression.19,20 HDACs are over-expressed in many malignancies21-25 and are believed to participate in malignant transformation through transcriptional repression of tumour suppressor genes.25-27 HDACs normally function together with cofactors that recruit HDACs to target genes28 and improper recruitment of HDACs by these cofactors has been identified as a mechanism for the development of malignancy.29,30 Fusion proteins generated by chromosomal translocations have also shown improper HDAC recruitment, particularly in leukaemia. Although the exact anti-tumour mechanisms of action of HDAC inhibitors are unknown, they have been shown to induce cell cycle arrest, proliferation and apoptosis in neoplastic cells.31-36
###end p 13
###begin p 14
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 442 444 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
For unknown reasons, CTCL has been the malignant disease with the highest clinical response so far to HDAC inhibitors. Thus, all three small molecule hydroxamates, vorinostat (SAHA), panobinostat (LBH-589) and belinostat (PXD101), as well as the natural product romidepsin (depsipeptide), have demonstrated response rates above 24% in CTCL,37 and vorinostat has been approved by the Food and Drug Administration for this indication as ZolinzaTM ().
###end p 14
###begin p 15
Despite this marked sensitivity of CTCL to HDAC inhibitors, studies on HDAC expression in CTCL are lacking. The aim of this study was to improve our understanding of HDAC involvement in the development of CTCL. Thus, we examined the expression of HDAC1, HDAC2 and HDAC6 together with the acetylation of histone H4 in CTCL tissue samples and correlated these results with the histological subtype and clinical outcome.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and tissue samples
###end title 17
###begin p 18
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
Formalin-fixed paraffin-embedded samples from skin lesions from 73 patients diagnosed with primary CTCL during the period 1979-2004 were drawn from the archives of the Department of Pathology, Copenhagen University Hospital. None of the patients participated in clinical trials for HDAC inhibitors. The clinical records were reviewed and all samples were examined by morphology and immunohistochemistry, using as a minimum CD3, CD5, CD4, CD8, CD56 and CD30. Based upon these data, the specimens were reclassified according to the World Health Organization-European Organization for Research and Treatment of Cancer classification and comprised 32 cases of MF with plaque lesions, seven cases of MF with tumour lesions, five cases of MF with transformation to large T-cell lymphoma, four cases of SS, seven cases of CD30+ primary cutaneous anaplastic large cell lymphoma (ALCL), 12 cases of CD30- peripheral T-cell lymphoma (PTL) not otherwise specified (NOS), two cases of extranodal natural killer/T-cell neoplasm, nasal type and four cases classified as precursor plasmacytoid dendritic cell neoplasm. These cases were grouped into two categories, i.e. indolent CTCL, comprising MF plaque, MF tumour and CD30+ large cell lymphoma; and aggressive CTCL, comprising the remaining disease categories.
###end p 18
###begin p 19
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Information on the clinical outcome could be retrieved in 59 (80.1%) of the cases. The overall survival for these patients ranged from 1 to 360 months, with large variations within each category (Table 1).
###end p 19
###begin p 20
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Clinical data from 59 cutaneous T-cell lymphoma (CTCL) patients showing number of patients, range in overall survival and median survival within each CTCL category
###end p 20
###begin p 21
Primary cutaneous anaplastic large cell lymphoma.
###end p 21
###begin p 22
Peripheral T-cell lymphoma, not otherwise specified.
###end p 22
###begin p 23
Precursor plasmacytoid dendritic cell neoplasm.
###end p 23
###begin title 24
Control cell lines
###end title 24
###begin p 25
###xml 215 216 214 215 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 10 15 <span type="species:ncbi:9606">human</span>
###xml 434 440 <span type="species:ncbi:10090">murine</span>
###xml 800 806 <span type="species:ncbi:9913">bovine</span>
The A2780 human ovarian cancer cell line (gift from Dr R. Ozols, Fox Chase Cancer Ctr. Philadelphia, PA, USA) was used as the positive control in the immunohistochemical analyses. Thus, A2780 cells treated with 1 mum belinostat (TopoTarget A/S, Copenhagen, Denmark) for 24 h were used as the positive control for H4 acetylation, whereas untreated A2780 cells were used as negative controls for the absence of H4 acetylation. The P388 murine leukaemia cell line, (gift from F. M. Shabel, SRI, Birmingham, AL, USA) together with a clone of P388 lacking HDAC2 (P388/2C clone 1) was used as the control for HDAC2 expression. Untreated A2780 cells were used as positive controls for reactivity of anti-HDAC1 and anti-HDAC6. Negative controls were performed by substituting the specific antibodies with 2% bovine serum albumin (BSA) in Tris-buffered saline (TBS) (pH 7.6).
###end p 25
###begin title 26
Tests for antibody specificity
###end title 26
###begin p 27
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 428 429 427 428 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Primary antibodies were monoclonal anti-HDAC1 (Upstate, Temecula, CA, USA; 05-614), monoclonal anti-HDAC2 (Abcam, Cambridge, MA, USA; ab12169), polyclonal anti-HDAC6 (Abcam; ab1440) and monoclonal anti-acetylated H4 (clone T25 developed by Ronzoni et al.38). An initial test for antibody specificity was performed by Western blotting using either whole-cell lysates or histones purified from P388 cells after treatment with 1 mum belinostat for 1 h. Blots were incubated with each of the primary antibodies before development. The appearance of only one band verified antibody specificity. The specificity of each anti-HDAC antibody was further tested in an immunohistochemical absorption assay against the corresponding HDAC peptide (gift from CuraGen Corporation, Branford, CT, USA). The antibody was incubated with excess amount of peptide prior to immunohistochemical analysis. Immunonegativity was then considered to be final proof of antibody specificity.
###end p 27
###begin title 28
Immunohistochemical analysis
###end title 28
###begin p 29
###xml 93 94 93 94 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 111 112 111 112 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
Heat-induced epitope retrieval was performed using Tris-hydrochloride (TEG) buffer pH 9 (10 mm Tris-HCl + 0.5 mm ethylene glycol tetraacetic acid) for retrieval of HDAC1, HDAC6, and acetylated H4 or Target Retrieval Solution, Citrate pH 6 (Dako, Glostrup, Denmark; S2369) for retrieval of HDAC2. Peroxidase Blocking Reagent (Dako; S2001) was used for blocking endogen peroxidase activity. Slides were pre-incubated in 2% BSA in TBS (pH 7.6) before primary antibodies were added. Dilution of primary antibodies was: anti-HDAC1 (1:2000), anti-HDAC2 (1:12 000), anti-HDAC6 (1:50) and anti-acetylated H4 (1:13 000). EnVision+ (Dako; K4001/K4003) and diaminobenzidene (DAB)+ (Dako; K3468) were used as the detection system. Slides were counterstained with Mayer's haematoxylin.
###end p 29
###begin p 30
Scoring of immunohistochemistry was based on two parameters: the number of immunopositive tumour cells and their intensity of immunoreactivity. Four different scores were given for the number of positive tumour cells, i.e. 0, <5%; 1, >5% to </=20%; 2, >20% to </=50%; and 3, >50% positive cells. Intensity of positivity was given a score of 0 for no positivity, 1 for weak positivity, 2 for moderate positivity and 3 for strong positivity. The sum of the two individual scores defined the final immunoreactivity score of each sample, ending up with seven groups with scores between 0 and 6. Finally, in order to ensure a sufficient number of samples in each group for statistical analysis, the samples were grouped in three expression categories defined as low (score 0-2), moderate (score 3 and 4) or high (score 5 and 6) expression. All reactions were simultaneously scored by two observers (L.M., E.R.) using a double-headed microscope.
###end p 30
###begin title 31
Statistical analyses
###end title 31
###begin p 32
###xml 762 763 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The comparison of the probability of expression of HDAC1, HDAC2, HDAC6 and acetylated H4 was done using a repeated measures linear model with ordinal categorical data. Tests for independence between immunohistochemical data and diagnostic groups were done using the chi-squared test with exact probabilities. Spearman rank correlation was calculated as a measure of association between the HDACs and H4 acetylation. Survival was calculated from the day of diagnosis until death or last follow-up. Survival probabilities were estimated by the Kaplan-Meier method and the log rank statistic was used to compare survival curves. Multivariate analysis of protein expression adjusted for indolent/aggressive disease was done using the Cox proportional hazards model. P-values <5% were considered to be significant.
###end p 32
###begin title 33
Ethical aspects
###end title 33
###begin p 34
This study was approved by the local ethics committee in Copenhagen, Denmark (Journal No. 01 326034) and the Danish Data Protection Agency (Journal No. 2006 41 7116).
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
Expression of HDACs and acetylated H4 in non-lymphoid cells
###end title 36
###begin p 37
In addition to immunoreactivity of lymphoid cells (see below), the antibodies against HDAC1, HDAC2 and acetylated H4 showed nuclear labelling of epithelial cells in the epidermis and dermal appendages. The antibody against HDAC6 stained the cytoplasm in these cells and also labelled the cytoplasm in endothelial cells. This reactivity of non-lymphoid cells served as useful internal controls for the immunohistochemical reactions.
###end p 37
###begin title 38
Expression of HDACs and acetylated H4 in CTCL cells
###end title 38
###begin p 39
In lymphoid cells, HDAC1, HDAC2 and acetylated H4 were expressed in the nuclei, whereas HDAC6 was mainly cytoplasmic with only weak reactivity of the nuclei in occasional cells. All four antibodies mainly labelled neoplastic cells with atypical nuclei, whereas small, reactive appearing lymphoid cells were negative.
###end p 39
###begin p 40
###xml 261 269 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1</xref>
###xml 314 322 314 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2</xref>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
Three categories were distinguished based upon the proportion of positive cells and the intensity of immunoreactivity, i.e. low, moderate and high (see Materials and methods). The distribution of all CTCL patients according to these categories is summarized in Figure 1. Representative examples are illustrated in Figure 2.
###end p 40
###begin p 41
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Expression profiles of HDAC1, HDAC2, HDAC6 and H4 acetylation in cutaneous T-cell lymphoma (CTCL) (n = 73) showing the percentage of samples in each of three categories of immunoreactivity (low, moderate, high). Significant differences in expression profiles are found between HDAC1 and HDAC2 (P < 0.0001) and HDAC2 and HDAC6 (P < 0.0001), whereas HDAC6 and acetylated H4 have similar profiles (P = 0.36).
###end p 41
###begin p 42
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 198 199 198 199 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 316 317 316 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 470 471 470 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 537 538 537 538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 639 640 639 640 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
A, Mycosis fungoides (MF), plaque stage with high expression of HDAC1 in the nuclei of the lymphoid infiltrate. Note that HDAC1 is also expressed in the nuclei in epithelial cells of the epidermis. B, Cutaneous T-cell lymphoma (CTCL), unspecified with high expression of HDAC2 in the nuclei of the neoplastic cells. C, MF, tumour stage with high HDAC6 expression in the cytoplasm. Note that HDAC6 is also expressed in the cytoplasm of epithelial cells of the epidermis. D, MF, tumour stage, negative of HDAC6 in the lymphoid infiltrate. E, CTCL, unspecified with high acetylation of histone H4. Small reactive lymphoid cells are negative. F, Precursor plasmacytoid dendritic cell neoplasm negative for H4 acetylation.
###end p 42
###begin p 43
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
As shown, HDAC1 was expressed most abundantly, followed by HDAC2 (P = 0.002) and HDAC6 (P < 0.0001). HDAC6 and acetylated H4 were equally frequently expressed (P = 0.36).
###end p 43
###begin title 44
Expression of HDACs and acetylated H4 in CTCL categories
###end title 44
###begin p 45
###xml 79 86 79 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 216 217 216 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
The relationship between immunoreactivity and CTCL categories is summarized in Table 2. Comparisons between indolent and aggressive cases regarding expression of HDAC1 and HDAC6 did not show significant differences (P = 0.35 and P = 0.89, respectively). In contrast, both HDAC2 (P = 0.001) and H4 acetylation (P = 0.03) were significantly more common in aggressive than in indolent CTCL. For HDAC2, 55.5% of the aggressive cases showed high expression. Conversely, among indolent CTCL, most cases (82.6%) showed only moderate HDAC2 expression. A similar finding was observed with H4 acetylation, where 22.2% of the aggressive cases showed high expression compared with only 8.7% of the indolent cases. Low H4 acetylation was observed in 30.4% of the indolent cases, whereas only 7.4% of the aggressive cases showed low H4 acetylation. When comparing the expression profiles in patients with indolent and aggressive subtypes, respectively, weak correlations in the expression were observed between all four parameters, i.e. HDAC1, 2, 6, and acetylated H4 (data not shown).
###end p 45
###begin p 46
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Expression of HDAC1, HDAC2, HDAC6, and acetylated H4 (H4ace) in different subtypes of cutaneous T-cell lymphoma (CTCL) (n = 73). Data show the number and percentage of samples within each group
###end p 46
###begin p 47
Primary cutaneous anaplastic large cell lymphoma.
###end p 47
###begin p 48
Peripheral T-cell lymphoma, not otherwise specified.
###end p 48
###begin p 49
Precursor plasmacytoid dendritic cell neoplasm.
###end p 49
###begin title 50
Expression of HDACs and acetylated histone H4 in CTCL versus survival
###end title 50
###begin p 51
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 311 319 311 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
###xml 753 761 749 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Figure 4</xref>
###xml 860 867 856 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 955 956 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Overall survival was available for 59 patients. As expected, median survival was significantly different between the indolent and aggressive groups, i.e. 84 months for patients with indolent CTCL compared with 28.5 months for patients with more aggressive disease (P < 0.0001). These results are illustrated in Figure 3. To investigate the impact of HDACs and acetylated H4 on survival in indolent and aggressive CTCL we used the Cox-model to adjust for the subtype and examined the influence of negative (score</= 2) versus positive (score > 2) expression. For HDAC2, we examined the influence of moderate (score</= 4) versus high (score > 4) expression, due to the fact that no samples showed negative or weak expression. Survival curves are shown in Figure 4. Cox analyses showed no significant influence on survival for HDAC1, HDAC2, or acetylated H4 (see Table 3). In contrast, HDAC6 expression showed a significant beneficial influence on survival [P = 0.04, hazard ratio (HR) 0.39, 95% confidence interval 0.16, 0.96] independent of the CTCL subtype.
###end p 51
###begin p 52
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Results of Cox analyses showing P-values, hazard ratios (HR), and 95% confidence intervals (CI)
###end p 52
###begin p 53
The group of indolent subtypes is used as reference to examine the influence of HDAC1, HDAC2, HDAC6, and acetylated H4 on survival. The parameter 'aggressive' demonstrates the negative influence of aggressive cutaneous T-cell lymphoma (CTCL) subtype on survival.
###end p 53
###begin p 54
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Overall survival of cutaneous T-cell lymphoma (CTCL) patients (n = 59) based on indolent versus aggressive subtype. Survival is significantly inferior in aggressive to that in indolent CTCL.
###end p 54
###begin p 55
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Overall survival of cutaneous T-cell lymphoma (CTCL) patients with either indolent or aggressive subtypes based on expression of HDAC1, HDAC2, HDAC6, or acetylated H4. Cox analysis revealed no significant influence of HDAC1, HDAC2, or H4 acetylation on survival. In contrast, HDAC6 was found to have a significantly beneficial influence on survival.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
Overexpression and improper recruitment of HDACs, particular HDAC1 and HDAC2, have been reported in different malignancies,21-23,25,30,39-41 emphasizing their role in malignant development. Although the influence of HDAC6 in cancer is not as well investigated as for HDAC1 and HDAC2, HDAC6 has been reported to be up-regulated in oral squamous cell carcinoma and the inhibition of HDAC6 has been reported to induce cytotoxicity in multiple myeloma cells as well as to reduce the amount of Bcr-Abl in leukaemia cells.42-44 The presumptive role of HDACs in malignant diseases has resulted in widespread development of HDAC inhibitors. For as yet unknown reasons, the malignancy most sensitive to HDAC inhibitors is CTCL.
###end p 57
###begin p 58
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 1181 1183 1181 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 1508 1510 1508 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 1511 1513 1511 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 579 586 <span type="species:ncbi:9606">patient</span>
###xml 764 772 <span type="species:ncbi:9606">patients</span>
###xml 807 815 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
###xml 1131 1139 <span type="species:ncbi:9606">patients</span>
###xml 1256 1264 <span type="species:ncbi:9606">patients</span>
###xml 1290 1298 <span type="species:ncbi:9606">patients</span>
###xml 1413 1421 <span type="species:ncbi:9606">patients</span>
Several clinical trials have examined the sensitivity of CTCL to HDAC inhibitors. Vorinostat, panobinostat, belinostat and romidepsin have all shown efficacy in CTCL with partial and complete responses. Interestingly, HDAC inhibitors have demonstrated equal efficacy in indolent and advanced stages of CTCL in patients who have failed prior systemic therapies. Thus, vorinostat resulted in a response rate of 20-31% in indolent stages (MF stage < IIB) compared with a response rate of 25-30% in advanced stages (MF stage IIB-IVB). All responses were partial (PR), except for one patient with MF stage IIB, who had a complete response (CR).45,46 Belinostat has shown efficacy in a phase II clinical trial against recurrent and refractory CTCL with CR in one of two patients with ALCL and PRs in two of eight patients with MF and one of four patients with SS.47 Romidepsin has also shown efficacy in clinical trials. Thus, treatment with romidepsin has resulted in an overall response rate of 31%, with PRs reported in SS as well as plaque/patch and tumour stages of MF. CRs have also been reported in patients with SS together with patients with PTL, unspecified, and CD30+ ALCL.48-50 Finally, panobinostat has demonstrated a response rate of six out of 10 patients with advanced-stage CTCL patients, with two CRs and four PRs.51 Although objective responses, i.e. complete or partial, are not reached by all CTCL patients, many still benefit from treatment by achieving stable disease and/or pruritus relief.45-47
###end p 58
###begin p 59
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 739 741 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
Only few immunohistochemical studies have examined the role of HDACs in cancer development and these have focused mainly on solid tumours. Thus, overexpression of HDAC1 and HDAC2 have been reported in gastric cancer23,39 and, in addition, HDAC2 has been associated with gastric tumour aggressiveness.39 Furthermore, HDAC1, HDAC2 and HDAC3 are up-regulated in colonic tumours compared with adjacent normal mucosa.24,52,53 Up-regulation of HDAC1 and nuclear accumulation of HDAC4 have been reported in primary and hormone refractory prostatic cancer compared with benign prostatic hyperplasia.21,22,54 However, in another study no difference was found in the level of HDAC1 expression between normal and malignant prostatic epithelial cells.55
###end p 59
###begin p 60
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">57</xref>
In our study, HDAC1 was more abundantly expressed than HDAC2, HDAC6 and acetylated H4. Acetylated H4 and HDAC6 were less expressed in CTCL. The expression profile of H4 acetylation in our study is similar to previous findings in prostatic cancer.56 Further, we found significant differences between the expression profiles of HDAC1 and HDAC2. This is in accordance with previous findings in other types of tumour.53,57 Our results further emphasize the unique functions of HDAC1 and HDAC2, despite their close sequence similarity.
###end p 60
###begin p 61
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HDAC1</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">58</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
The influence of HDAC1 and HDAC6 on tumour aggressiveness is controversial. Thus, HDAC1 gene expression was up-regulated in the indolent germinal centre B-cell subtype of diffuse large B-cell lymphoma compared with the more aggressive activated B-cell and type 3 subtypes.58,59 In contrast, in solid tumours HDAC1 was correlated with more advanced stages of lung cancer60 and HDAC6 showed a directly opposite influence in breast cancer and oral squamous cell carcinoma.44,61 In our study, we found no evidence for the involvement of HDAC1 or HDAC6 in the development of more aggressive CTCL based on their expression in indolent versus aggressive CTCL subtypes. In contrast, we found more extensive expression of HDAC2 in aggressive than indolent CTCL. This is in accordance with previous findings,24,39 indicating possible involvement of HDAC2 in aggressive CTCL.
###end p 61
###begin p 62
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
Several of the HDAC inhibitors in clinical trials are hydroxamate pan-inhibitors, e.g. vorinostat, belinostat, and panobinostat,37,37 whereas others such as MS275, MGCD0103 and romidepsin are subtype specific.18 Based on the current results as well as those obtained by Zhu et al.24 and Song et al.,39 it may be reasonable to develop an HDAC2-specific inhibitor. However, before any such decision is made, more information is needed on the influence of HDACs in malignancies as well as on the anti-tumour mechanism of HDAC inhibitors and how they act in different tumours.
###end p 62
###begin p 63
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">63</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">64</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">65</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66">66</xref>
The influence of H4 acetylation in malignancy is questionable. Gain of function mutations in HAT enzymes have been identified in different types of cancer and could in turn lead to increased histone acetylation.62 Furthermore, hyperacetylation of H4 is partly caused by loss of function of HDAC1 in chronic myeloid leukaemia.63 Thus, H4 hyperacetylation may be a result and not a cause of cancer development. We found that acetylation of H4 was more pronounced in aggressive than in indolent CTCL. In contrast, malignant progression of oesophageal squamous cell carcinoma has been correlated to H4 hypoacetylation.64,65 In our study, three PTL, unspecified, showed high H4 acetylation. Interestingly, histone acetylation has been shown to up-regulate the development of T-cell receptor gamma gene recombination at least in thymocytes.66 Thus, high H4 acetylation may play a role in lymphoma development.
###end p 63
###begin p 64
###xml 231 238 231 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b67">67</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">68</xref>
###xml 679 686 679 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">69</xref>
###xml 1016 1023 1016 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">65</xref>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
###xml 1096 1104 <span type="species:ncbi:9606">patients</span>
When comparing the influence of HDAC expression and acetylated H4 on survival, HDAC1 did not show significant results. However, a HR <1 suggests that increased HDAC1 expression correlates with better survival in CTCL patients (see Table 3). This is in accordance with previous findings showing that HDAC1 expression is associated with better survival in breast cancer patients, at least in those with small and well-differentiated tumours.67,68 We could not demonstrate that HDAC2 had an influence on survival. In contrast, HDAC6 expression had a significant influence on survival, with a HR <1, indicating a favourable influence on survival independent of the CTCL subtype (see Table 3). This result agrees with previous findings showing that HDAC6 expression is correlated with better survival in oestrogen receptor-positive breast cancer patients.61,69 Even though acetylated H4 does not show a significant influence on survival, a HR >1 indicates a possible negative influence of H4 acetylation on survival (see Table 3). This is in contrast to previous findings showing better prognosis for patients with a high level of acetylated H4.65
###end p 64
###begin p 65
In conclusion, we have found that overexpression of HDAC6 had a beneficial influence on survival and that this was independent of the CTCL subtype. Further, high expression of HDAC2 and acetylated H4 was more common in aggressive than in indolent CTCL.
###end p 65
###begin title 66
References
###end title 66
###begin article-title 67
EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
###end article-title 67
###begin article-title 68
WHO-EORTC classification for cutaneous lymphomas
###end article-title 68
###begin article-title 69
###xml 230 238 <span type="species:ncbi:9606">patients</span>
Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients
###end article-title 69
###begin article-title 70
UVB in the management of early stage mycosis fungoides
###end article-title 70
###begin article-title 71
Management of the primary cutaneous lymphomas
###end article-title 71
###begin article-title 72
Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up
###end article-title 72
###begin article-title 73
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy
###end article-title 73
###begin article-title 74
Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation)
###end article-title 74
###begin article-title 75
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Topical corticosteroids for mycosis fungoides. Experience in 79 patients
###end article-title 75
###begin article-title 76
Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches
###end article-title 76
###begin article-title 77
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy
###end article-title 77
###begin article-title 78
Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions
###end article-title 78
###begin article-title 79
Primary cutaneous T-cell lymphoma: review and current concepts
###end article-title 79
###begin article-title 80
Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma
###end article-title 80
###begin article-title 81
CD56+ lymphoma with skin involvement: clinicopathologic features and classification
###end article-title 81
###begin article-title 82
Histone deacetylases (HDACs): characterization of the classical HDAC family
###end article-title 82
###begin article-title 83
Chromatin modifications as targets for new anticancer drugs
###end article-title 83
###begin article-title 84
Determination of the class and isoform selectivity of small molecule HDAC inhibitors
###end article-title 84
###begin article-title 85
Histone deacetylases and cancer: causes and therapies
###end article-title 85
###begin article-title 86
Histone acetylation in gene regulation
###end article-title 86
###begin article-title 87
###xml 49 54 <span type="species:ncbi:9606">human</span>
Histone deacetylase and DNA methyltransferase in human prostate cancer
###end article-title 87
###begin article-title 88
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer
###end article-title 88
###begin article-title 89
Expression profile of histone deacetylase 1 in gastric cancer tissues
###end article-title 89
###begin article-title 90
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
###end article-title 90
###begin article-title 91
Role of the histone deacetylase complex in acute promyelocytic leukaemia
###end article-title 91
###begin article-title 92
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
###end article-title 92
###begin article-title 93
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
###end article-title 93
###begin article-title 94
The coregulator exchange in transcriptional functions of nuclear receptors
###end article-title 94
###begin article-title 95
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
###end article-title 95
###begin article-title 96
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression
###end article-title 96
###begin article-title 97
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells
###end article-title 97
###begin article-title 98
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 81 89 81 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
###end article-title 98
###begin article-title 99
Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase
###end article-title 99
###begin article-title 100
Butyrate as a differentiating agent: pharmacokinetics, analogues and current status
###end article-title 100
###begin article-title 101
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
###end article-title 101
###begin article-title 102
The molecular mechanism of HDAC inhibitors in anticancer effects
###end article-title 102
###begin article-title 103
HDAC inhibitors: clinical update and mechanism-based potential
###end article-title 103
###begin article-title 104
New method to detect histone acetylation levels by flow cytometry
###end article-title 104
###begin article-title 105
###xml 58 63 <span type="species:ncbi:9606">human</span>
Increased expression of histone deacetylase 2 is found in human gastric cancer
###end article-title 105
###begin article-title 106
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
###end article-title 106
###begin article-title 107
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1
###end article-title 107
###begin article-title 108
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
###end article-title 108
###begin article-title 109
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors
###end article-title 109
###begin article-title 110
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma
###end article-title 110
###begin article-title 111
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
###end article-title 111
###begin article-title 112
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
###end article-title 112
###begin article-title 113
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Phase II open-label trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. EMSO Conference
###end article-title 113
###begin article-title 114
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
###end article-title 114
###begin article-title 115
Phase II trial of romidepsin, FK228, in cutaneous and peripheral T-cell lymphoma: clinical activity and molecular markers
###end article-title 115
###begin article-title 116
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Completion of the first cohort of patients with cutaneous T-cell lymphoma enrolled on a phase II trial of depsipeptide
###end article-title 116
###begin article-title 117
###xml 59 67 <span type="species:ncbi:9606">patients</span>
LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Skin gene expression profiles in the first 24 hours related to clinical response following therapy
###end article-title 117
###begin article-title 118
###xml 127 132 <span type="species:ncbi:9606">human</span>
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
###end article-title 118
###begin article-title 119
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
###end article-title 119
###begin article-title 120
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate
###end article-title 120
###begin article-title 121
###xml 55 60 <span type="species:ncbi:9606">human</span>
Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells
###end article-title 121
###begin article-title 122
Global histone modification patterns predict risk of prostate cancer recurrence
###end article-title 122
###begin article-title 123
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells
###end article-title 123
###begin article-title 124
Microarray-based classification of diffuse large B-cell lymphoma
###end article-title 124
###begin article-title 125
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
###end article-title 125
###begin article-title 126
Histone deacetylase 1 mRNA expression in lung cancer
###end article-title 126
###begin article-title 127
HDAC6 expression is correlated with better survival in breast cancer
###end article-title 127
###begin article-title 128
Histone acetylation and chromatin pattern in cancer. A review
###end article-title 128
###begin article-title 129
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors
###end article-title 129
###begin article-title 130
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma
###end article-title 130
###begin article-title 131
Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas
###end article-title 131
###begin article-title 132
Histone acetylation determines the developmentally regulated accessibility for T cell receptor gamma gene recombination
###end article-title 132
###begin article-title 133
###xml 51 56 <span type="species:ncbi:9606">human</span>
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis
###end article-title 133
###begin article-title 134
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
###end article-title 134
###begin article-title 135
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
###end article-title 135
###begin title 136
Abbreviations:
###end title 136
###begin p 137
anaplastic large cell lymphoma
###end p 137
###begin p 138
###xml 0 6 <span type="species:ncbi:9913">bovine</span>
bovine serum albumin
###end p 138
###begin p 139
complete response
###end p 139
###begin p 140
cutaneous T-cell lymphoma
###end p 140
###begin p 141
histone acetyltransferase
###end p 141
###begin p 142
histone deacetylase
###end p 142
###begin p 143
hazard ratio
###end p 143
###begin p 144
mycosis fungoides
###end p 144
###begin p 145
not otherwise specified
###end p 145
###begin p 146
partial response
###end p 146
###begin p 147
peripheral T-cell lymphoma
###end p 147
###begin p 148
Sezary syndrome
###end p 148
###begin p 149
Tris-buffered saline
###end p 149

